Standard

The Vascular Impairment of Cognition Classification Consensus Study. / VICCCS group.

In: Alzheimer's and Dementia, Vol. 13, No. 6, 06.2017, p. 624-633.

Research output: Contribution to journal › Article › peer-review

Harvard

VICCCS group 2017, 'The Vascular Impairment of Cognition Classification Consensus Study', Alzheimer's and Dementia, vol. 13, no. 6, pp. 624-633. https://doi.org/10.1016/j.jalz.2016.10.007

APA

VICCCS group (2017). The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 13(6), 624-633. https://doi.org/10.1016/j.jalz.2016.10.007

Vancouver

VICCCS group. The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia. 2017 Jun;13(6):624-633. https://doi.org/10.1016/j.jalz.2016.10.007

Author

VICCCS group. / The Vascular Impairment of Cognition Classification Consensus Study. In: Alzheimer's and Dementia. 2017 ; Vol. 13, No. 6. pp. 624-633.

BibTeX

@article{52502b94164f4e2f82d21ca563c4045f,
title = "The Vascular Impairment of Cognition Classification Consensus Study",
abstract = "Introduction Numerous diagnostic criteria have tried to tackle the variability in clinical manifestations and problematic diagnosis of vascular cognitive impairment (VCI) but none have been universally accepted. These criteria have not been readily comparable, impacting on clinical diagnosis rates and in turn prevalence estimates, research, and treatment. Methods The Vascular Impairment of Cognition Classification Consensus Study (VICCCS) involved participants (81% academic researchers) from 27 countries in an online Delphi consensus study. Participants reviewed previously proposed concepts to develop new guidelines. Results VICCCS had a mean of 122 (98–153) respondents across the study and a 67% threshold to represent consensus. VICCCS redefined VCI including classification of mild and major forms of VCI and subtypes. It proposes new standardized VCI-associated terminology and future research priorities to address gaps in current knowledge. Discussion VICCCS proposes a consensus-based updated conceptualization of VCI intended to facilitate standardization in research.",
keywords = "Consensus, Criteria, Delphi, Guidelines, Vascular cognitive impairment, Vascular dementia",
author = "{VICCCS group} and Skrobot, {Olivia A.} and Seth Love and Kehoe, {Patrick G.} and John O'Brien and Sandra Black and Christopher Chen and Charles DeCarli and Timo Erkinjuntti and Ford, {Gary A.} and Kalaria, {Rajesh N.} and Leonardo Pantoni and Florence Pasquier and Roman, {Gustavo C.} and Anders Wallin and Perminder Sachdev and J. Kril and Ingmar Skoog and Yoav Ben-Shlomo and Passmore, {Anthony P.} and S. Engelborghs and C. Lafosse and Bertolucci, {P. H.} and S. Brucki and P. Caramelli and {de Toledo Ferraz Alves}, {T. C.} and C. Bocti and T. Fulop and Hogan, {D. B.} and Hsiung, {G. R.} and A. Kirk and L. Leach and A. Robillard and Sahlas, {D. J.} and Q. Guo and J. Tian and L. Hokkanen and H. Jokinen and S. Benisty and V. Deramecourt and J. Hauw and H. Lenoir and M. Tsatali and M. Tsolaki and U. Sundar and Coen, {R. F.} and Korczyn, {A. D.} and M. Altieri and M. Baldereschi and C. Caltagirone and Kruglov, {L. S.}",
note = "Funding Information: Declaration of interests: Prof. Ford reports personal fees from Pfizer, Athersys, AstraZeneca, Lundbeck, Cerevast, and Daiichi Sankyo and grants and personal fees from Boehringer Ingelheim, outside the submitted work. Prof. O'Brien reports personal fees from GE Healthcare, TauRx, and Cytox and grants and personal fees from Avid/Lilly, outside the submitted work. Prof. Skoog reports personal fees and other from Takeda, outside the submitted work. Outside the submitted work, Prof. Black reports institutional grants from Pfizer, GE Healthcare, Eli Lilly, Elan/Transition Therapeutics, Roche, and Cognoptix and personal fees from Pfizer, GE Healthcare, Eli Lilly, Eisai, Boehringer Ingelheim, and Novartis. Funding Information: This work was supported by a project grant (Ref117) from the Alzheimer's Society (UK). Publisher Copyright: {\textcopyright} 2016 the Alzheimer's Association Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2017",
month = jun,
doi = "10.1016/j.jalz.2016.10.007",
language = "English",
volume = "13",
pages = "624--633",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - The Vascular Impairment of Cognition Classification Consensus Study

AU - VICCCS group

AU - Skrobot, Olivia A.

AU - Love, Seth

AU - Kehoe, Patrick G.

AU - O'Brien, John

AU - Black, Sandra

AU - Chen, Christopher

AU - DeCarli, Charles

AU - Erkinjuntti, Timo

AU - Ford, Gary A.

AU - Kalaria, Rajesh N.

AU - Pantoni, Leonardo

AU - Pasquier, Florence

AU - Roman, Gustavo C.

AU - Wallin, Anders

AU - Sachdev, Perminder

AU - Kril, J.

AU - Skoog, Ingmar

AU - Ben-Shlomo, Yoav

AU - Passmore, Anthony P.

AU - Engelborghs, S.

AU - Lafosse, C.

AU - Bertolucci, P. H.

AU - Brucki, S.

AU - Caramelli, P.

AU - de Toledo Ferraz Alves, T. C.

AU - Bocti, C.

AU - Fulop, T.

AU - Hogan, D. B.

AU - Hsiung, G. R.

AU - Kirk, A.

AU - Leach, L.

AU - Robillard, A.

AU - Sahlas, D. J.

AU - Guo, Q.

AU - Tian, J.

AU - Hokkanen, L.

AU - Jokinen, H.

AU - Benisty, S.

AU - Deramecourt, V.

AU - Hauw, J.

AU - Lenoir, H.

AU - Tsatali, M.

AU - Tsolaki, M.

AU - Sundar, U.

AU - Coen, R. F.

AU - Korczyn, A. D.

AU - Altieri, M.

AU - Baldereschi, M.

AU - Caltagirone, C.

AU - Kruglov, L. S.

N1 - Funding Information: Declaration of interests: Prof. Ford reports personal fees from Pfizer, Athersys, AstraZeneca, Lundbeck, Cerevast, and Daiichi Sankyo and grants and personal fees from Boehringer Ingelheim, outside the submitted work. Prof. O'Brien reports personal fees from GE Healthcare, TauRx, and Cytox and grants and personal fees from Avid/Lilly, outside the submitted work. Prof. Skoog reports personal fees and other from Takeda, outside the submitted work. Outside the submitted work, Prof. Black reports institutional grants from Pfizer, GE Healthcare, Eli Lilly, Elan/Transition Therapeutics, Roche, and Cognoptix and personal fees from Pfizer, GE Healthcare, Eli Lilly, Eisai, Boehringer Ingelheim, and Novartis. Funding Information: This work was supported by a project grant (Ref117) from the Alzheimer's Society (UK). Publisher Copyright: © 2016 the Alzheimer's Association Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2017/6

Y1 - 2017/6

N2 - Introduction Numerous diagnostic criteria have tried to tackle the variability in clinical manifestations and problematic diagnosis of vascular cognitive impairment (VCI) but none have been universally accepted. These criteria have not been readily comparable, impacting on clinical diagnosis rates and in turn prevalence estimates, research, and treatment. Methods The Vascular Impairment of Cognition Classification Consensus Study (VICCCS) involved participants (81% academic researchers) from 27 countries in an online Delphi consensus study. Participants reviewed previously proposed concepts to develop new guidelines. Results VICCCS had a mean of 122 (98–153) respondents across the study and a 67% threshold to represent consensus. VICCCS redefined VCI including classification of mild and major forms of VCI and subtypes. It proposes new standardized VCI-associated terminology and future research priorities to address gaps in current knowledge. Discussion VICCCS proposes a consensus-based updated conceptualization of VCI intended to facilitate standardization in research.

AB - Introduction Numerous diagnostic criteria have tried to tackle the variability in clinical manifestations and problematic diagnosis of vascular cognitive impairment (VCI) but none have been universally accepted. These criteria have not been readily comparable, impacting on clinical diagnosis rates and in turn prevalence estimates, research, and treatment. Methods The Vascular Impairment of Cognition Classification Consensus Study (VICCCS) involved participants (81% academic researchers) from 27 countries in an online Delphi consensus study. Participants reviewed previously proposed concepts to develop new guidelines. Results VICCCS had a mean of 122 (98–153) respondents across the study and a 67% threshold to represent consensus. VICCCS redefined VCI including classification of mild and major forms of VCI and subtypes. It proposes new standardized VCI-associated terminology and future research priorities to address gaps in current knowledge. Discussion VICCCS proposes a consensus-based updated conceptualization of VCI intended to facilitate standardization in research.

KW - Consensus

KW - Criteria

KW - Delphi

KW - Guidelines

KW - Vascular cognitive impairment

KW - Vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=85013639675&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.10.007

DO - 10.1016/j.jalz.2016.10.007

M3 - Article

C2 - 27960092

AN - SCOPUS:85013639675

VL - 13

SP - 624

EP - 633

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 6

ER -

ID: 37620532